71 – 80 of 4740
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
(
- Contribution to journal › Article
-
Mark
Potential interplay between tumor size and vitamin D receptor (VDR) polymorphisms in breast cancer prognosis : a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Minimal invasive LASER-resection vs. radiotherapy as primary treatment of early glottic cancer. A population-based study with, up to 16 years follow up of survival, rate of laryngectomy and voice function
(
- Contribution to journal › Article
-
Mark
Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours
(
- Contribution to journal › Article
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
-
Mark
The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types
(
- Contribution to journal › Article
-
Mark
Register data on long-term morbidity after prostate cancer radiotherapy with ultra-hypofractionated (2.5 weeks) vs conventional (8 weeks) treatment schedules
2024) U21 Health Sciences Group 2024 Doctoral Student Forum(
- Contribution to conference › Poster
-
Mark
Correspondence to comment on : Impact of type 2 diabetes on complications after primary breast cancer surgery: Danish population-based cohort study
(
- Contribution to journal › Letter
-
Mark
Anti-Müllerian hormone and fertility in women after childhood cancer treatment : Association with current infertility risk classifications
(
- Contribution to journal › Article
-
Mark
High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome
(
- Contribution to journal › Article